Fresenius SE & Co. KGaA (FRE)
XETRA Stock Exchange · Germany · prices in EUR · close of 23 Oct 2026
Key indicators
| Last close | EUR 46.10 |
|---|---|
| 52-week range | 35.11 – 52.96 |
| Return, 1 month / 3 months | −0.3% / +7.6% |
| Return, 1 year / 3 years | −3.2% / +91.7% |
| Trend | Uptrend |
| RSI (14) | 60 |
| Volatility (1 year) | 24.9% |
| Worst drawdown (1 year) | -30.1% |
| Average daily value traded | 44.90M EUR |
| Dividend yield | 2.3% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Fresenius is a German healthcare group based in Bad Homburg that provides products and services for hospitals, clinics and patients. Its divisions supply infusion therapy, clinical nutrition and generic intravenous medicines, and it runs dialysis care through Fresenius Medical Care, which also makes dialysis equipment. Another arm operates private hospitals and outpatient facilities, mainly in Europe and Latin America, while a further division offers services for healthcare facilities and international health projects.
The shares are listed on the XETRA Stock Exchange in Germany under the code FRE, and the price on this page is in euros (EUR). Our dividend records, which start in 2019, show payments in 7 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Fresenius SE & Co. KGaA (FRE) trades on the XETRA Stock Exchange in Germany. It last closed at EUR 46.10 on 23 October 2026.
Its price-based Market X-Ray is 68 out of 100 (a fair price profile), ranking 141 of 701 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 3.2% and over the last three months it rose 7.6%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on XETRA Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 67 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 5.6% | ||
| From 52-week high | -11.6% | ||
| Momentum | 66 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 7.6% | ||
| 6-month return | 16.4% | ||
| 12-month return, skipping the last month | -2.9% | ||
| Stability (higher is calmer) | 67 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 24.9% | ||
| Worst drawdown, 1 year (smaller is calmer) | -30.1% | ||
| Liquidity | 97 · Strong | Trades actively. | |
| Average daily value traded | 44.90M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 31 · Weak | Dividend is small or irregular. | |
| Dividend yield | 2.3% | ||
| Years with dividends | 4 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | +2.3% |
|---|---|
| 1 month | −0.3% |
| 3 months | +7.6% |
| 6 months | +16.4% |
| 1 year | −3.2% |
| 3 years | +91.7% |
| 5 years | +25.7% |
Signals
| 50-day / 200-day average | 44.98 / 43.65 |
|---|---|
| Golden / death cross (60 days) | Golden, 38 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.00 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 25 May 2026 | EUR 1.0500 |
| 26 May 2025 | EUR 1.0000 |
| 18 May 2023 | EUR 0.9200 |
| 16 May 2022 | EUR 0.9200 |
| 24 May 2021 | EUR 0.8800 |
| 31 Aug 2020 | EUR 0.8385 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on XETRA Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.